Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Asset Writedowns and Impairment (2024 - 2025)

Historic Asset Writedowns and Impairment for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Q2 2025 value amounting to -$80000.0.

  • Phathom Pharmaceuticals' Asset Writedowns and Impairment fell 13292.18% to -$80000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $939000.0, marking a year-over-year increase of 3114.53%. This contributed to the annual value of $836000.0 for FY2024, which is N/A changed from last year.
  • As of Q2 2025, Phathom Pharmaceuticals' Asset Writedowns and Impairment stood at -$80000.0, which was down 13292.18% from $899000.0 recorded in Q1 2025.
  • Phathom Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $899000.0 during Q1 2025, with a 5-year trough of -$80000.0 in Q2 2025.